Indaptus Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
On June 17, 2026, Indaptus completed a $12.0M private placement, issuing 20M shares at $0.60/share. Concurrently, the company discontinued enrollment and wound down all Decoy20 clinical studies, eliminating active clinical development programs. As of June 30, 2026, cash/investments totaled $11.6M ($7.6M cash + $4.0M short-term investments). R&D expenses fell 83% YoY to $0.4M (Q2), and net loss improved to $1.8M (Q2) vs. $5.2M prior year. The company is now evaluating strategic alternatives including research collaborations (newly begun in neurological disorders/sleep), potential acquisitions, or investments in other businesses.
Why this rating
Raised capital extends runway (positive), but termination of lead clinical program and shift to strategic review indicate core program failure/pivot—material negative for $5.8M market cap.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.